Form 4 Filing for Athira Pharma, Inc.

This filing details significant transactions by Perceptive Advisors LLC and its affiliated entities concerning Athira Pharma, Inc. (ATHA). On December 23, 2025, these entities acquired a substantial number of securities, including common stock and various warrants (Pre-Funded, Series A, and Series B). The transactions involved the purchase of common stock, with Perceptive Life Sciences Master Fund Ltd. acquiring 989,270 shares and Perceptive Xontogeny Venture Fund II, LP acquiring 329,756 shares, both at a price of $6.35 per share. Additionally, numerous warrants were acquired, including Pre-Funded Warrants, Series A Warrants, and Series B Warrants, with associated prices and underlying common stock shares detailed in the filing. Footnotes indicate that the combined purchase price often included shares of common stock along with accompanying warrants. The filing also notes beneficial ownership exclusions and limitations, particularly the 19.99% beneficial ownership limitation for the reporting persons and a 4.99% limitation for Sermonix Pharmaceuticals, Inc. regarding the exercise of these warrants.